Key result
SGLT2 inhibitors reduce incident HF in T2D while strict glycemic control shows unclear benefit.
Why the study?
Diabetes mellitus and heart failure are closely linked to increased morbidity and mortality, but the role of strict glycemic control in reducing heart failure remains unclear.
Highlights the bidirectional relationship between diabetes and heart failure, the mechanisms of diabetic cardiomyopathy, and the importance of SGLT2 inhibitors in treatment.
May guide joint diabetes-HF management; leaves open prospective trials on cardiomyopathy mechanisms.
There is a close relationship between diabetes mellitus and heart failure, both of which are known to increase morbidity and mortality.Diabetes can cause or aggravate heart failure, and heart failure can precipitate diabetes.Diabetes mellitus causes structural and functional changes in the heart, such as fibrosis of the myocardium and left ventricular dysfunction.The mechanisms of diabetic cardiomyopathy are metabolic disturbance, myocardial fibrosis, microvascular disease, and autonomic dysfunction.Improper blood glucose control leads to deterioration of heart failure, but the role of strict glycemic control in reducing heart failure is unclear.The role of SGLT2 inhibitors in reducing the incidence of heart failure is of great importance in the treatment of diabetic patients.However, further long-term follow-up and safety studies are needed.
No takes yet. Share an insight, caveat, or question.
Sang‐Hoon Seol (2019) conducted a review in Type 2 Diabetes and Heart Failure. SGLT2 inhibitors and other diabetes medications was evaluated. SGLT2 inhibitors are of great importance in reducing the incidence of heart failure in patients with type 2 diabetes, whereas the role of strict glycemic control remains unclear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: